Compare Accenture plc (ACN) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Danaher Corporation — how do they compare? Accenture plc trades at $137.9 (market cap $86.98B), while Danaher Corporation trades at $190.62 (market cap $137.44B). The key difference: Danaher Corporation is the larger of the two by market cap, and Accenture plc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ACN | DHR | |
|---|---|---|
Market Cap | $86.98B | $137.44B |
Sector | Technology | Health |
52-Week High | $303.33 | $242.05 |
52-Week Low | $124.41 | $161.91 |
Enterprise Value | $85.20B | $150.22B |
Dividend Yield | 4.59% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $137.19, up 0.17% on the day, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 11.35, net income margin of 10.66%, and consistent earnings beats in recent quarters. Recent news highlights strategic AI partnerships with TEPCO Solution Advance and AlphaSense, reinforcing its focus on digital transformation services. Operating cash flow strengthened to $11.47 billion in 2025, supporting dividend payments and growth initiatives.
The outlook for ACN is positive, driven by strong analyst sentiment with a consensus price target of $193.92 and 66% buy ratings. Key opportunities include revenue growth from AI adoption and global consulting demand. Risks involve competitive pressures, macroeconomic sensitivity, and execution challenges in integrating new technologies. The stock offers value with reasonable valuation multiples and a track record of profitability.
Danaher (DHR) trades at $190.77, down 1.47% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains solid fundamentals with consistent earnings beats, a 14.89% net income margin, and positive cash flow of $2.54B in 2025. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment.
The stock presents a compelling opportunity with 69% analyst buy ratings and a $214.73 price target suggesting 12.6% upside. Key risks include revenue stagnation from $24.6B in 2025 to projected $24.8B in 2026 and the recent $172.5M legal settlement over pandemic-era disclosures. Biotechnology segment growth at 7% remains a positive catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
